Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-30

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI)

NCT00820937

Lewy Body Dementia

COMPLETED NA

The GBA Multimodal Study in Parkinson's Disease

NCT04101968

Parkinson Disease GBA Gene Mutation Gaucher Disease

RECRUITING

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

NCT00209456

Lewy Body Dementia Non-DLB Dementia Alzheimer's +1 more

COMPLETED PHASE3

Single Photon Emission Computed Tomography (SPECT) to Study Paroxysmal Hyperkinetic Movement Disorders

NCT00051337

Hyperkinesis

COMPLETED

[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD

NCT06120049

Parkinson Disease Dementia With Lewy Bodies MSA - Multiple System Atrophy +1 more

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

There are several types of cameras allowing its performance:

* Conventional Anger cameras and,
* CZT (Cadmium-Zinc-Telluride) semiconductor cameras. At the Nancy University Hospital, the nuclear medicine department has a wide-field Cadmium-Zinc-Telluride camera: VERITON-CT (Spectrum Dynamics). The interpretation of this examination is purely visual.

The objectives are therefore to:

* Create the first international database of semi-quantitative values in 3D scintigraphy with Datscan performed with a VERITON-CT camera.
* Compare this database with another database from a conventional Anger camera (Lyon Nuclear Medicine Department) to show its superiority.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurodegenerative Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

datscan scintigraphy

Semi-quantitative analysis on Datscan imaging scintigraphy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients who have undergone a Datscan scintigraphy on the VERITON camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, -Absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease.
* The clinical diagnosis can only be established after two years of clinical follow-up.

Exclusion Criteria

* Excluded from this research will be the patients opposed to the use of their data, minors, atypical Parkinsonian syndromes,
* patients who died before two years of clinical follow-up,
* patients who had their Datscan examination carried out on a camera other than the VERITON and - patients lost to follow-up.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No